TQB2825 Injection (Subcutaneous Injection)
TQB2825-I-02
Phase 1 small_molecule active
Quick answer
TQB2825 Injection (Subcutaneous Injection) for CD20-positive Hematological Malignancies is a Phase 1 program (small_molecule) at Shanghai University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Shanghai University of Traditional Chinese Medicine
- Indication
- CD20-positive Hematological Malignancies
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active